Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
- Details
- Category: Roche
![Roche Roche](/images/logo/roche.png)
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- Details
- Category: Business
![CPHI Barcelona 2023 CPHI Barcelona 2023](/images/logo/cphi_barcelona.png)
U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
More Pharma News ...
- Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Bayer to partner with Twist Bioscience to accelerate drug discovery
- Novartis shareholders approve the proposed 100% Spin-off of Sandoz
- Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
- GSK and Save the Children renew award-winning partnership, with focus on 'zero dose' children who have never received a vaccine
- Roche's Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
- BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint